Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedFooter now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1.SummaryDifference0.0%

- Check18 days agoChange DetectedRevision reflects an update from v3.4.0 to v3.4.1 with no visible changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check32 days agoChange DetectedAdded Show glossary / Hide glossary options and updated metadata labels to reflect Revision: v3.4.0 (Last Update Submitted that Met QC Criteria; No FEAR Act Data).SummaryDifference0.3%

- Check39 days agoChange DetectedRevision: v3.3.4 appears alongside the previous v3.3.3 revision, indicating a small maintenance update with no impact on the study details or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check68 days agoChange DetectedLocations section reorganized to include a Colorado entry under a general Locations header; the Colorado Locations subheading was removed, and the revision label updated to v3.3.3 with the HHS Vulnerability Disclosure link removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check90 days agoChange DetectedAdded: These publications are automatically filled in from PubMed, a public database of scientific and medical articles, and may or may not be about the study; Revision: v3.3.2. Deleted: These publications come from PubMed, this list is automatically created by ClinicalTrials.gov Identifier (NCT Number), and these articles may or may not be about the study; Revision: v3.2.0.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.